StockUS listing USRPTXNASDAQHealthcareProfitless Growth

Repare Therapeutics Inc(RPTX) Stock Analysis | Healthcare

USD --+0.00%
Reward59Moderate
Risk47Moderate
75%Data
Revenue down 77% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 114.24M
Reward Ratingⓘ59 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ47 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RPTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Repare Therapeutics Inc?

, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.

AI Brief Pro

The brief on Repare Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Repare Therapeutics Inc?

, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 114.24M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (59)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap114.24M
Beta0.962
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.